Valuation: Vivos Inc.

Market Cap 29.44M 25.81M 23.79M 22.27M 41.76M 2.78B 42.63M 286M 111M 1.37B 111M 108M 4.76B P/E 2024
-16.2x
P/E 2025 -10.2x
Enterprise Value 27.99M 24.54M 22.62M 21.18M 39.72M 2.64B 40.54M 272M 105M 1.31B 105M 103M 4.53B EV / Sales 2024
1,724x
EV / Sales 2025 438x
Free-Float
95.83%
Yield 2024 *
-
Yield 2025 -
1 day-0.84%
1 week-7.66%
Current month-14.22%
1 month-15.21%
3 months-33.97%
6 months-15.45%
Current year-14.22%
1 week 0.06
Extreme 0.058
0.07
1 month 0.06
Extreme 0.0558
0.07
Current year 0.06
Extreme 0.0558
0.09
1 year 0.04
Extreme 0.0425
0.15
3 years 0.04
Extreme 0.0412
0.26
5 years 0.04
Extreme 0.04
0.26
10 years 0.01
Extreme 0.0065
8
Manager TitleAgeSince
Chief Executive Officer 79 2016-12-13
President 44 2025-09-14
Corporate Secretary 81 2016-12-13
Director TitleAgeSince
Chairman 81 2016-12-13
Director/Board Member 79 2017-08-01
Date Insider Type Main position Quantity % Market Cap.
05-10Buy

Chief Executive Officer

150,000 0.0311%
12-30Buy

Chief Executive Officer

200,000 0.0440%
12-01Buy

Chief Executive Officer

100,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
-0.84%-7.66%-50.34%+11.51% 29.44M
-3.22%-5.07%-23.78%-26.57% 12.25B
-6.66%-12.39%+64.37%+9.52% 4.93B
-0.44%+0.83%+52.29%+87.95% 1.2B
-4.01%-5.67%-40.58%-66.78% 1.19B
-3.99%-11.87%-42.78%-49.47% 1.09B
-3.49%-7.80%-44.64% - 903M
-3.51%-14.31%+152.43%+159.16% 622M
+7.65%+9.41% - - 349M
+2.86%+2.29%-56.29%+209.17% 255M
Average -1.60%-3.82%+1.19%+41.81% 2.28B
Weighted average by Cap. -3.66%-5.19%+1.45%-7.11%

Financials

2024 2025
Net sales 28K 24.55K 22.63K 21.18K 39.72K 2.64M 40.55K 272K 105K 1.31M 105K 103K 4.53M 68.38K 59.95K 55.26K 51.74K 97.02K 6.45M 99.03K 664K 257K 3.19M 257K 251K 11.05M
Net income -2.91M -2.55M -2.35M -2.2M -4.13M -275M -4.22M -28.27M -10.94M -136M -10.93M -10.69M -471M -3.07M -2.69M -2.48M -2.32M -4.35M -289M -4.44M -29.78M -11.52M -143M -11.51M -11.26M -496M
Net Debt -2.21M -1.94M -1.79M -1.67M -3.14M -209M -3.2M -21.49M -8.32M -103M -8.31M -8.13M -358M -1.44M -1.27M -1.17M -1.09M -2.05M -136M -2.09M -14.03M -5.43M -67.33M -5.42M -5.3M -233M
Logo Vivos Inc.
Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Employees
1
Date Price Change Volume
26-06-26 US$0.0591 -0.84% 585,677
26-06-25 US$0.0596 -0.67% 1,106,330
26-06-24 US$0.0600 -5.78% 913,947
26-06-23 US$0.0637 -0.50% 299,451
26-06-22 US$0.0640 +1.75% 460,313
  1. Stock Market
  2. Stocks
  3. RDGL Stock